LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Art Pappas to moderate panel, "Accessing Capital through Risk-Sharing Models between Early-Stage Companies and Contract Research Organizations" at BIO 2010 in Chicago, IL
News | 05. 05. 2010
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.